Back to top Open menu arrow
Purchase PDF Reprints
Sections
METHODS RESULTS DISCUSSION CONCLUSION Clinical Points
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

Meta-Analysis May 4, 2021

Marine Omega-3 Fatty Acid Supplementation for Borderline Personality Disorder: A Meta-Analysis

; ;

J Clin Psychiatry 2021;82(3):20r13613

ABSTRACT

Objective: Several promising studies investigated marine omega-3 fatty acids (ie, fish oil) in borderline personality disorder (BPD), but overall effects remain unclear. The aim of this study was to obtain estimates of effectiveness of omega-3 fatty acids in BPD using meta-analysis, with a priori differentiation of affective, impulsive, and cognitive-perceptual symptom domains.

Data Sources: We performed a literature search in PubMed, EMBASE, PsycINFO, and MEDLINE, using terms related to BPD and omega-3 fatty acids. Publication date was not a restriction.

Study Selection: We included randomized controlled trials (RCTs) that compared omega-3 fatty acids to placebo or any active comparator and pooled data using meta-analysis. Five studies were included in the meta-analysis, describing 4 RCTs testing effects of omega-3 fatty acids in 137 patients with BPD or BPD-related behavior.

Data Extraction: Using a pre-piloted data extraction form, we obtained data including intervention dose, duration, and BPD symptom scale scores, differentiating affective, impulsive, and cognitive-perceptual symptom domains.

Results: Random effects meta-analysis showed an overall significant decreasing effect of omega-3 fatty acids on overall BPD symptom severity (0.54 standardized difference in means [SDM]; 95% CI = 0.91 to 0.17; Z = 2.87; P = .0041), without heterogeneity (I2 = 0.00; Q = 2.63; P = .45). A priori differentiation of relevant symptom domains showed significant effects on affect dysregulation (0.74 SDM; 95% CI = 1.21 to 0.27; Z = 3.11; P = .002) and impulsive behavior (0.45 SDM; 95% CI = 0.84 to 0.059; Z = 2.26; P = .024). However, effects on cognitive-perceptual symptoms did not reach the significance threshold.

Conclusions: Available data indicate that marine omega-3 fatty acids improve symptoms of BPD, particularly impulsive behavioral dyscontrol and affective dysregulation. Marine omega-3 fatty acids could be considered as add-on therapy.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Buy PDF for $40

Please sign in or purchase this PDF for $40.

  1. Bender DS, Skodol AE. Borderline personality as a self-other representational disturbance. J Pers Disord. 2007;21(5):500–517. PubMed CrossRef
  2. Pompili M, Girardi P, Ruberto A, et al. Suicide in borderline personality disorder: a meta-analysis. Nord J Psychiatry. 2005;59(5):319–324. PubMed CrossRef
  3. Hastrup LH, Jennum P, Ibsen R, et al. Societal costs of borderline personality disorders: a matched-controlled nationwide study of patients and spouses. Acta Psychiatr Scand. 2019;140(5):458–467. PubMed CrossRef
  4. National Collaborating Centre for Mental Health (UK). Borderline Personality Disorder: Treatment and Management. NICE Clinical Guidelines, No. 78. British Psychological Society; 2009.
  5. Ingenhoven T, Lafay P, Rinne T, et al. Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry. 2010;71(1):14–25. PubMed CrossRef
  6. Soloff PH. Algorithms for pharmacological treatment of personality dimensions: symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation. Bull Menninger Clin. 1998;62(2):195–214. PubMed
  7. Ingenhoven T. Pharmacotherapy for borderline patients: business as usual or by default? J Clin Psychiatry. 2015;76(4):e522–e523. PubMed CrossRef
  8. Drews E, Fertuck EA, Koenig J, et al. Hypothalamic-pituitary-adrenal axis functioning in borderline personality disorder: a meta-analysis. Neurosci Biobehav Rev. 2019;96:316–334. PubMed CrossRef
  9. Thomas N, Gurvich C, Hudaib A-R, et al. Systematic review and meta-analysis of basal cortisol levels in borderline personality disorder compared to non-psychiatric controls. Psychoneuroendocrinology. 2019;102:149–157. PubMed CrossRef
  10. Wingenfeld K, Dettenborn L, Kirschbaum C, et al. Reduced levels of the endocannabinoid arachidonylethanolamide (AEA) in hair in patients with borderline personality disorder—a pilot study. Stress. 2018;21(4):366–369. PubMed CrossRef
  11. Blaney C, Sommer J, El-Gabalawy R, et al; CIHR Team in Defining the Burden and Managing the Impact of Psychiatric Comorbidity in Immune-Mediated Inflammatory Disease. Incidence and temporal trends of co-occurring personality disorder diagnoses in immune-mediated inflammatory diseases. Epidemiol Psychiatr Sci. 2020;29:e84. PubMed CrossRef
  12. Díaz-Marsá M, Macdowell KS, Guemes I, et al. Activation of the cholinergic anti-inflammatory system in peripheral blood mononuclear cells from patients with borderline personality disorder. J Psychiatr Res. 2012;46(12):1610–1617. PubMed CrossRef
  13. MacDowell KS, Marsá MD, Buenache E, et al. Inflammatory and antioxidant pathway dysfunction in borderline personality disorder. Psychiatry Res. 2020;284:112782. PubMed CrossRef
  14. Anderson G. Pathoetiology and pathophysiology of borderline personality: role of prenatal factors, gut microbiome, mu- and kappa-opioid receptors in amygdala-PFC interactions. Prog Neuropsychopharmacol Biol Psychiatry. 2020;98:109782. PubMed CrossRef
  15. O’Neill A, Frodl T. Brain structure and function in borderline personality disorder. Brain Struct Funct. 2012;217(4):767–782. PubMed CrossRef
  16. Mocking RJT, Assies J, Ruhé HG, et al. Focus on fatty acids in the neurometabolic pathophysiology of psychiatric disorders. J Inherit Metab Dis. 2018;41(4):597–611. PubMed CrossRef
  17. Hibbeln JR, Linnoila M, Umhau JC, et al. Essential fatty acids predict metabolites of serotonin and dopamine in cerebrospinal fluid among healthy control subjects, and early- and late-onset alcoholics. Biol Psychiatry. 1998;44(4):235–242. PubMed CrossRef
  18. Pawełczyk T, Grancow-Grabka M, Trafalska E, et al. An increase in plasma brain derived neurotrophic factor levels is related to n-3 polyunsaturated fatty acid efficacy in first episode schizophrenia: secondary outcome analysis of the OFFER randomized clinical trial. Psychopharmacology (Berl). 2019;236(9):2811–2822. PubMed CrossRef
  19. Giacobbe J, Benoiton B, Zunszain P, et al. The anti-inflammatory role of omega-3 polyunsaturated fatty acids metabolites in pre-clinical models of psychiatric, neurodegenerative, and neurological disorders. Front Psychiatry. 2020;11:122. PubMed CrossRef
  20. Freeman MP, Hibbeln JR, Wisner KL, et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry. 2006;67(12):1954–1967. PubMed CrossRef
  21. Assies J, Pouwer F, Lok A, et al. Plasma and erythrocyte fatty acid patterns in patients with recurrent depression: a matched case-control study. PLoS One. 2010;5(5):e10635. PubMed CrossRef
  22. Zaalberg A, Vanhouche, A-S, Smoyer A, et al. Voeding En Justitiabelen: Van Strafelement Naar Rehabilitatie-Instrument? Wetenschappelijk Onderzoek- en Documentatiecentrum; 2018.
  23. Individueel zorgplan en behandeling. In: Depressieve Stoornissen. GGZ Standaarden; 2018. https://www.ggzstandaarden.nl/zorgstandaarden/depressieve-stoornissen/individueel-zorgplan-en-behandeling
  24. Firth J, Teasdale SB, Allott K, et al. The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry. 2019;18(3):308–324. PubMed CrossRef
  25. Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. PubMed CrossRef
  26. Stoffers‐Winterling JM, Storebø OJ, Völlm BA, et al. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev. 2018(2):CD012956. CrossRef
  27. Mocking RJ, Harmsen I, Assies J, et al. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl Psychiatry. 2016;6(3):e756. PubMed CrossRef
  28. Higgins JPT, Altman DG, Gøtzsche PC, et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. PubMed CrossRef
  29. Guyatt GH, Oxman AD, Schünemann HJ, et al. GRADE guidelines: a new series of articles in The Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64(4):380–382. PubMed CrossRef
  30. Upton J. Beck Depression Inventory (BDI). In: Gellman MD, Turner JR, eds. Encyclopedia of Behavioral Medicine. Springer New York; 2013:178–179.
  31. Gonzalez JS, Shreck E, Batchelder A. Hamilton Rating Scale for Depression (HAM-D). In: Gellman MD, Turner JR, eds. Encyclopedia of Behavioral Medicine. Springer New York; 2013:887–888.
  32. Coccaro EF. The Overt Aggression Scale Modified (OAS-M) for clinical trials targeting impulsive aggression and intermittent explosive disorder: validity, reliability, and correlates. J Psychiatr Res. 2020;124:50–57. PubMed CrossRef
  33. Dougherty DM, Marsh DM, Mathias CW. Immediate and delayed memory tasks: a computerized behavioral measure of memory, attention, and impulsivity. Behav Res Methods Instrum Comput. 2002;34(3):391–398. PubMed CrossRef
  34. Hall RCW, Parks J. The modified global assessment of functioning scale: addendum. Psychosomatics. 1995;36(4):416–417. PubMed CrossRef
  35. Kay SR, Opler LA, Lindenmayer J-P. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry suppl. 1989;155(7):59–67. PubMed CrossRef
  36. Quilty LC, Robinson JJ, Rolland JP, et al. The structure of the Montgomery-Åsberg Depression Rating Scale over the course of treatment for depression. Int J Methods Psychiatr Res. 2013;22(3):175–184. PubMed CrossRef
  37. Giesen-Bloo JH, Wachters LM, Schouten E, et al. The Borderline Personality Disorder Severity Index-IV: psychometric evaluation and dimensional structure. Pers Individ Dif. 2010;49(2):136–141. CrossRef
  38. Maier W, Buller R, Philipp M, et al. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord. 1988;14(1):61–68. PubMed CrossRef
  39. Reise SP, Moore TM, Sabb FW, et al. The Barratt Impulsiveness Scale-11: reassessment of its structure in a community sample. Psychol Assess. 2013;25(2):631–642. PubMed CrossRef
  40. Sansone RA, Wiederman MW, Sansone LA. The Self-Harm Inventory (SHI): development of a scale for identifying self-destructive behaviors and borderline personality disorder. J Clin Psychol. 1998;54(7):973–983. PubMed CrossRef
  41. Rybarczyk B. Social and Occupational Functioning Assessment Scale (SOFAS). In: Kreutzer JS, DeLuca J, Caplan B, eds. Encyclopedia of Clinical Neuropsychology. Springer New York; 2011:2313.
  42. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28–37. PubMed
  43. Ingenhoven TJ, Duivenvoorden HJ. Differential effectiveness of antipsychotics in borderline personality disorder: meta-analyses of placebo-controlled, randomized clinical trials on symptomatic outcome domains. J Clin Psychopharmacol. 2011;31(4):489–496. PubMed CrossRef
  44. Zanarini MC, Frankenburg FR. omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry. 2003;160(1):167–169. PubMed CrossRef
  45. Bellino S, Bozzatello P, Rocca G, et al. Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid. J Psychopharmacol. 2014;28(2):125–132. PubMed CrossRef
  46. Bozzatello P, Rocca P, Bellino S. Combination of omega-3 fatty acids and valproic acid in treatment of borderline personality disorder: a follow-up study. Clin Drug Investig. 2018;38(4):367–372. PubMed CrossRef
  47. Hallahan B, Hibbeln JR, Davis JM, et al. Omega-3 fatty acid supplementation in patients with recurrent self-harm: single-centre double-blind randomised controlled trial. Br J Psychiatry. 2007;190(2):118–122. PubMed CrossRef
  48. Amminger GP, Chanen AM, Ohmann S, et al. Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial. Can J Psychiatry. 2013;58(7):402–408. PubMed CrossRef
  49. Buydens-Branchey L, Branchey M. Long-chain n-3 polyunsaturated fatty acids decrease feelings of anger in substance abusers. Psychiatry Res. 2008;157(1–3):95–104. PubMed CrossRef
  50. Long SJ, Benton D. A double-blind trial of the effect of docosahexaenoic acid and vitamin and mineral supplementation on aggression, impulsivity, and stress. Hum Psychopharmacol. 2013;28(3):238–247. PubMed CrossRef
  51. Mocking RJT, Steijn K, Roos C, et al. Omega-3 fatty acid supplementation for perinatal depression: a meta-analysis. J Clin Psychiatry. 2020;81(5):19r13106. PubMed CrossRef
  52. Sutin AR, Milaneschi Y, Cannas A, et al. Impulsivity-related traits are associated with higher white blood cell counts. J Behav Med. 2012;35(6):616–623. PubMed CrossRef
  53. Sutin AR, Terracciano A, Deiana B, et al. High neuroticism and low conscientiousness are associated with interleukin-6. Psychol Med. 2010;40(9):1485–1493. PubMed CrossRef
  54. Suchankova P, Holm G, Träskman-Bendz L, et al. The +1444C>T polymorphism in the CRP gene: a study on personality traits and suicidal behaviour. Psychiatr Genet. 2013;23(2):70–76. PubMed CrossRef
  55. Peet M, Brind J, Ramchand CN, et al. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res. 2001;49(3):243–251. PubMed CrossRef
  56. Jamilian H, Solhi H, Jamilian M. Randomized, placebo-controlled clinical trial of omega-3 as supplemental treatment in schizophrenia. Glob J Health Sci. 2014;6(7 spec no):103–108. PubMed
  57. Roberts DJ, Goralski KB. A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain. Expert Opin Drug Metab Toxicol. 2008;4(10):1245–1264. PubMed CrossRef
  58. Wongrattanakamon P, Lee VS, Nimmanpipug P, et al. Nucleotide-binding domain 1 modelling: a novel molecular docking approach for screening of P-glycoprotein inhibitory activity of bioflavonoids. Chemical Data Collections. 2016;2:10–16. CrossRef
  59. Mollazadeh S, Sahebkar A, Hadizadeh F, et al. Structural and functional aspects of P-glycoprotein and its inhibitors. Life Sci. 2018;214:118–123. PubMed CrossRef
  60. Wang JS, Taylor R, Ruan Y, et al. Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacology. 2004;29(3):551–557. PubMed CrossRef
  61. El Ela AA, Härtter S, Schmitt U, et al. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds—implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004;56(8):967–975. PubMed CrossRef
Buy PDF for $40

Please sign in or purchase this PDF for $40.

Save Save

Share Share

Cite Cite

Vol 86 • 2025 • Number 1

Read the Current Issue

Brief Report

Sex Differences in PTSD among US Military Veterans

Commentary

The Opioid Industry's Legacy: A Generation of Prescribed Suffering

Clinical and Practical Psychopharmacology

Cannabis Use in Pregnancy and ASD or ADHD in Offspring

Commentary

Evolving Care and Research Priorities in ADHD

Original Research

Treatments and Treatment Predictors in Patients With SUDs and ADHD

Systematic Review

Efficacy and Safety of Memantine for Children and Adults with ADHD
View current Issue

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe